TouchRESPIRATORY got the opportunity to catch up with Dr. David Fleischer (Children’s Hospital Colorado, Aurora, CO, USA) to discuss the current available therapies and future of the treatment paradigm for peanut allergy.
Questions
- How has the approval of Palforzia impacted the treatment paradigm for peanut allergies? (0:14)
- What questions remain unanswered regarding oral immunotherapies and what future studies are planned/ongoing? (1:56)
- What is the latest status of the Viaskin peanut patch approval bid? (3:34)
- What other routes of immunotherapy are being investigated and which seems the most promising? (5:22)
- What other therapeutic approaches are emerging? (6:47)
Disclosures: David Fleischer discloses consulting for DBV Technologies and clinical trial funding to the University from DBV Technologies, and Aimmune Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
